Market Summary
USD22.47-0.13
Market Closed-0.58%
VCYT Alerts
VCYT Stock Price
VCYT RSI Chart
VCYT Valuation
VCYT Price/Sales (Trailing)
VCYT Profitability
VCYT Fundamentals
VCYT Revenue
VCYT Earnings
Price Action
52 Week Range
14.9231.09
(Low)(High)
Last 7 days
-10.3%
Last 30 days
-14.4%
Last 90 days
-12.0%
Trailing 12 Months
34.5%
VCYT Financial Health
VCYT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for VCYT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-02 | Wygant Jonathan | sold (taxes) | -33,294 | 26.7 | -1,247 | vp, chief accounting officer |
2023-09-02 | Stapley Marc | sold (taxes) | -85,546 | 26.7 | -3,204 | chief executive officer |
2023-09-02 | Chambers Rebecca | sold (taxes) | -97,508 | 26.7 | -3,652 | chief financial officer |
2023-09-02 | McGuire Annie | sold (taxes) | -46,164 | 26.7 | -1,729 | svp, general counsel |
2023-09-02 | Leite John | sold (taxes) | -59,327 | 26.7 | -2,222 | chief commercial officer-clia |
2023-07-19 | JONES EVAN/ FA | sold | -93,232 | 30.1723 | -3,090 | - |
2023-07-19 | JONES EVAN/ FA | sold | -25,257 | 30.1398 | -838 | - |
2023-07-18 | JONES EVAN/ FA | sold | -224,616 | 30.1863 | -7,441 | - |
2023-07-18 | BISHOP JOHN L | acquired | 63,700 | 6.37 | 10,000 | - |
2023-07-18 | JONES EVAN/ FA | sold | -70,089 | 30.1591 | -2,324 | - |
Which funds bought or sold VCYT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 21.63 | 1,265,000 | 4,514,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 47.00 | 382 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | reduced | -4.17 | 31,533 | 365,163 | 0.09% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | 31,053 | 249,504 | 0.01% |
2023-08-22 | COMERICA BANK | new | - | 34,000 | 34,000 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.22 | 233,622 | 2,233,820 | -% |
2023-08-21 | VitalStone Financial, LLC | unchanged | - | -1,000 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 0.98 | 59,534 | 446,865 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 13.97 | 227,000 | 979,000 | 0.01% |
2023-08-18 | Legato Capital Management LLC | added | 36.37 | 422,262 | 1,179,590 | 0.16% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
VCYT Alerts
Schedule 13G FIlings of Veracyte
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 09, 2023 | wellington management group llp | 10.01% | 7,248,889 | SC 13G/A | |
| Feb 09, 2023 | william blair investment management, llc | 0.8% | 558,384 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.55% | 6,852,657 | SC 13G/A | |
| Feb 06, 2023 | state street corp | 5.80% | 4,159,331 | SC 13G | |
| Feb 06, 2023 | wellington management group llp | 9.25% | 6,636,543 | SC 13G/A | |
| Jan 25, 2023 | blackrock inc. | 9.1% | 6,534,569 | SC 13G/A | |
| Feb 14, 2022 | nikko asset management americas, inc. | 4.39% | 3,121,103 | SC 13G/A | |
| Feb 10, 2022 | invesco ltd. | 5.8% | 4,114,031 | SC 13G/A | |
| Feb 09, 2022 | ark investment management llc | 11.57% | 8,222,281 | SC 13G/A | |
| Feb 04, 2022 | artisan partners limited partnership | 7.0% | 4,956,409 | SC 13G/A |
Recent SEC filings of Veracyte
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 06, 2023 | 3 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 10-Q | Quarterly Report | |
| Aug 08, 2023 | 8-K | Current Report | |
| Jul 24, 2023 | 4 | Insider Trading | |
| Jul 19, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Veracyte)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 269.9B | 56.0B | 3.85% | 7.89% | 31.08 | 4.82 | -2.31% | -31.27% |
VRTX | 90.1B | 9.5B | -0.31% | 22.07% | 26.78 | 9.48 | 13.83% | 5.33% |
REGN | 88.3B | 12.7B | -1.90% | 19.84% | 20.53 | 6.97 | -10.94% | -24.40% |
INCY | 13.0B | 3.5B | -10.13% | -13.81% | 35.41 | 3.69 | 5.81% | -61.22% |
| MID-CAP | ||||||||
NTRA | 5.2B | 931.0M | -16.86% | -0.76% | -10.21 | 5.61 | 28.69% | 11.08% |
ARWR | 2.9B | 256.2M | -4.82% | -13.52% | -16.11 | 11.39 | 2.51% | -17.66% |
| SMALL-CAP | ||||||||
VCYT | 1.6B | 328.6M | -14.37% | 34.47% | -56.17 | 4.97 | 22.46% | 40.27% |
CSTL | 442.5M | 167.5M | -10.46% | -33.92% | -4.98 | 2.64 | 52.01% | -99.69% |
CDNA | 413.7M | 309.3M | -12.66% | -52.30% | -4.93 | 1.34 | -1.76% | -21.01% |
ORGO | 317.8M | 457.3M | -9.02% | -24.14% | 31.63 | 0.69 | -0.61% | -85.93% |
CELC | 220.2M | - | -2.83% | 14.20% | -4.49 | - | - | -59.74% |
NVTA | 176.8M | 493.9M | -33.66% | -73.83% | -0.22 | 0.36 | -1.39% | 74.28% |
OPGN | 1.6M | 2.8M | 29.38% | -44.90% | -0.04 | 0.57 | -31.25% | -41.90% |
Veracyte News
Returns for VCYT
Cumulative Returns on VCYT
17.2%
7-Year Cumulative Returns
17.5%
5-Year Cumulative Returns
-10.7%
3-Year Cumulative Returns
Risks for VCYT
What is the probability of a big loss on VCYT?
100%
Probability that Veracyte stock will be more than 20% underwater in next one year
67.7%
Probability that Veracyte stock will be more than 30% underwater in next one year.
45.4%
Probability that Veracyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does VCYT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Veracyte was unfortunately bought at previous high price.
Drawdowns
Financials for Veracyte
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 5.6% | 328,633,000 | 311,175,000 | 296,536,000 | 283,575,000 | 268,353,000 | 250,594,000 | 219,514,000 | 186,714,000 | 157,465,000 | 123,064,000 | 117,483,000 | 112,677,000 | 112,529,000 | 121,961,000 | 120,368,000 | 116,388,000 | 108,881,000 | 101,496,000 | 92,008,000 | 85,854,000 | 79,907,000 |
| Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36,077,000 | 35,108,000 | 34,255,000 | 33,724,000 | 33,078,000 | 32,143,000 | 31,051,000 |
| Costs and Expenses | 4.3% | 362,282,000 | 347,506,000 | 337,617,000 | 331,569,000 | 323,348,000 | 302,330,000 | 301,417,000 | 264,356,000 | 222,492,000 | 191,668,000 | 152,872,000 | 148,191,000 | 145,740,000 | 147,221,000 | 135,495,000 | 126,375,000 | 121,409,000 | 116,841,000 | 114,241,000 | 111,074,000 | 107,191,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114,241,000 | - | - |
| S&GA Expenses | 1.8% | 101,691,000 | 99,936,000 | 97,560,000 | 95,645,000 | 91,637,000 | 87,298,000 | 79,840,000 | 70,777,000 | 60,062,000 | 51,101,000 | 52,389,000 | 53,423,000 | 55,556,000 | 58,798,000 | 53,691,000 | 49,574,000 | 46,567,000 | 42,247,000 | 41,313,000 | 40,292,000 | 38,096,000 |
| R&D Expenses | 7.2% | 47,370,000 | 44,206,000 | 40,603,000 | 39,568,000 | 36,801,000 | 33,673,000 | 29,843,000 | 24,177,000 | 20,213,000 | 18,133,000 | 17,204,000 | 17,061,000 | 16,662,000 | 15,823,000 | 14,851,000 | 13,533,000 | 13,309,000 | 14,580,000 | 14,820,000 | 14,897,000 | 14,524,000 |
| EBITDA | 100.0% | - | -4,003,000 | -10,490,000 | -18,527,000 | -25,423,000 | -26,846,000 | -61,998,000 | -63,099,000 | -55,731,000 | -60,107,000 | -26,736,000 | -28,364,000 | -39,046,000 | -41,291,000 | -7,806,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.01 | -0.04 | -0.07 | -0.09 | -0.11 | -0.28 | -0.34 | -0.35 | -0.49 | -0.23 | -0.25 | -0.35 | -0.34 | -0.06 | - | - | - | - | - | - |
| Interest Expenses | - | - | - | 9,000 | - | - | 63,000 | 9,000 | 73,000 | 128,000 | 130,000 | 13,000 | -89,000 | -86,000 | 84,000 | 332,000 | 1,132,000 | 1,572,000 | 1,818,000 | 1,963,000 | 3,945,000 | 4,262,000 |
| Earnings Before Taxes | 4.6% | -28,684,000 | -30,054,000 | -36,427,000 | -44,254,000 | -50,858,000 | -50,401,000 | -81,600,000 | -78,376,000 | -67,021,000 | -68,856,000 | -34,909,000 | -35,820,000 | -45,482,000 | -46,864,000 | -12,599,000 | - | - | - | - | - | - |
| EBT Margin | 100.0% | - | -0.10 | -0.12 | -0.16 | -0.19 | -0.20 | -0.37 | -0.42 | -0.43 | -0.56 | -0.30 | -0.32 | -0.40 | -0.38 | -0.10 | - | - | - | - | - | - |
| Net Income | 3.7% | -29,060,000 | -30,190,000 | -36,560,000 | -43,244,000 | -48,650,000 | -48,156,000 | -75,563,000 | -73,079,000 | -63,074,000 | -65,061,000 | -34,909,000 | -34,323,000 | -30,929,000 | -22,398,000 | -12,599,000 | -8,246,000 | -11,985,000 | -15,739,000 | -22,999,000 | -28,333,000 | -30,913,000 |
| Net Income Margin | 100.0% | - | -0.10 | -0.12 | -0.15 | -0.18 | -0.19 | -0.34 | -0.39 | -0.40 | -0.53 | -0.30 | -0.30 | -0.27 | -0.18 | -0.10 | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 7,146,000 | -1,014,000 | -1,281,000 | -9,798,000 | -6,565,000 | -36,997,000 | -43,229,000 | -38,907,000 | -48,339,000 | -12,548,000 | -13,231,000 | -16,136,000 | -10,178,000 | -5,988,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.3% | 1,161 | 1,157 | 1,156 | 1,126 | 1,144 | 1,174 | 1,188 | 1,186 | 1,027 | 1,025 | 457 | 454 | 257 | 267 | 275 | 260 | 252 | 124 | 121 | 119 | 65.00 |
| Current Assets | 3.2% | 259 | 252 | 249 | 239 | 235 | 238 | 243 | 229 | 371 | 362 | 376 | 370 | 173 | 181 | 188 | 228 | 220 | 91.00 | 97.00 | 95.00 | 42.00 |
| Cash Equivalents | 7.4% | 191 | 178 | 154 | 170 | 154 | 164 | 174 | 165 | 328 | 325 | 349 | 346 | 148 | 154 | 160 | 196 | 193 | 68.00 | 79.00 | 78.00 | 24.00 |
| Inventory | -13.0% | 12.00 | 13.00 | 14.00 | 14.00 | 15.00 | 12.00 | 11.00 | 10.00 | 7.00 | 6.00 | 5.00 | 4.00 | 7.00 | 6.00 | 7.00 | 7.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 |
| Net PPE | - | - | - | - | - | - | - | - | - | 12.00 | 11.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 9.00 |
| Goodwill | -0.1% | 699 | 700 | 696 | 677 | 690 | 704 | 708 | 714 | 472 | 475 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Liabilities | 3.3% | 78.00 | 76.00 | 81.00 | 78.00 | 80.00 | 88.00 | 91.00 | 79.00 | 56.00 | 51.00 | 36.00 | 31.00 | 31.00 | 37.00 | 36.00 | 29.00 | 28.00 | 40.00 | 41.00 | 40.00 | 40.00 |
| Current Liabilities | 3.9% | 58.00 | 56.00 | 63.00 | 58.00 | 59.00 | 63.00 | 64.00 | 50.00 | 36.00 | 33.00 | 17.00 | 14.00 | 13.00 | 19.00 | 17.00 | 17.00 | 15.00 | 14.00 | 13.00 | 10.00 | 10.00 |
| LT Debt, Current | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | 1.00 | - | - |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 13.00 | 24.00 | 25.00 | 25.00 |
| Shareholder's Equity | 0.1% | 1,083 | 1,081 | 1,075 | 1,048 | 1,064 | 1,085 | 1,097 | 1,107 | 971 | 974 | 421 | 423 | 226 | 230 | 239 | 231 | 224 | 84.00 | 80.00 | 79.00 | 26.00 |
| Retained Earnings | -2.1% | -410 | -401 | -393 | -389 | -381 | -371 | -357 | -346 | -332 | -323 | -281 | -273 | -269 | -258 | -246 | -239 | -238 | -236 | -234 | -230 | -226 |
| Additional Paid-In Capital | 0.7% | 1,521 | 1,510 | 1,500 | 1,492 | 1,483 | 1,477 | 1,469 | 1,462 | 1,304 | 1,298 | 703 | 696 | 496 | 489 | 486 | 470 | 463 | 320 | 314 | 310 | 252 |
| Shares Outstanding | 0.4% | 73.00 | 72.00 | 72.00 | 72.00 | 71.00 | 71.00 | 71.00 | 70.00 | 67.00 | 63.00 | 58.00 | 55.00 | 50.00 | 50.00 | 50.00 | 49.00 | 46.00 | 41.00 | 37.00 | 39.00 | 34.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 119.7% | 31.00 | 14.00 | 8.00 | 6.00 | -2.18 | 0.00 | -31.62 | -37.81 | -34.66 | -44.97 | -9.71 | -10.18 | -13.49 | -7.52 | -3.23 | -6.25 | -6.47 | -7.12 | -13.52 | -18.11 | -21.43 |
| Share Based Compensation | 15.8% | 33.00 | 28.00 | 27.00 | 27.00 | 27.00 | 25.00 | 23.00 | 19.00 | 15.00 | 14.00 | 13.00 | 12.00 | 12.00 | 11.00 | 10.00 | 8.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 |
| Cashflow From Investing | 197.5% | 3.00 | -2.85 | -29.39 | -2.57 | -176 | -166 | -739 | -740 | -576 | -578 | -3.84 | -44.05 | -42.64 | -42.65 | -42.73 | -2.09 | -2.52 | -2.40 | -1.87 | -1.72 | -1.79 |
| Cashflow From Financing | 14.8% | 4.00 | 3.00 | 3.00 | 4.00 | 5.00 | 7.00 | 596 | 599 | 793 | 795 | 204 | 204 | 11.00 | 135 | 127 | 126 | 178 | 50.00 | 59.00 | 56.00 | 0.00 |
VCYT Income Statement
2023-06-30Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 90,322 | $ 72,864 | $ 172,744 | $ 140,647 |
| Operating expenses: | ||||
| Research and development | 12,541 | 9,377 | 25,310 | 18,543 |
| Selling and marketing | 25,756 | 24,001 | 51,886 | 47,755 |
| General and administrative | 25,047 | 19,798 | 47,510 | 40,710 |
| Intangible asset amortization | 5,341 | 5,391 | 10,670 | 10,877 |
| Total operating expenses | 98,373 | 83,597 | 191,293 | 166,628 |
| Loss from operations | (8,051) | (10,733) | (18,549) | (25,981) |
| Other income (loss), net | (226) | 1,086 | 2,181 | 1,870 |
| Loss before income taxes | (8,277) | (9,647) | (16,368) | (24,111) |
| Income tax expense (benefit) | 125 | (115) | 125 | (118) |
| Net loss | $ (8,402) | $ (9,532) | $ (16,493) | $ (23,993) |
| Net loss per common share, basic (in USD per share) | $ (0.12) | $ (0.13) | $ (0.23) | $ (0.34) |
| Net loss per common share, diluted (in USD per share) | $ (0.12) | $ (0.13) | $ (0.23) | $ (0.34) |
| Shares used to compute net loss per common share, basic (in shares) | 72,478,662 | 71,476,966 | 72,327,897 | 71,354,002 |
| Shares used to compute net loss per common share, diluted (in shares) | 72,478,662 | 71,476,966 | 72,327,897 | 71,354,002 |
| Testing revenue | ||||
| Revenue: | ||||
| Total revenue | $ 81,749 | $ 59,718 | $ 154,145 | $ 115,698 |
| Operating expenses: | ||||
| Cost of revenue | 23,333 | 18,584 | 42,981 | 36,107 |
| Product revenue | ||||
| Revenue: | ||||
| Total revenue | 4,011 | 3,108 | 7,903 | 6,087 |
| Operating expenses: | ||||
| Cost of revenue | 2,315 | 1,646 | 4,477 | 3,221 |
| Biopharmaceutical and other revenue | ||||
| Revenue: | ||||
| Total revenue | 4,562 | 10,038 | 10,696 | 18,862 |
| Operating expenses: | ||||
| Cost of revenue | $ 4,040 | $ 4,800 | $ 8,459 | $ 9,415 |
VCYT Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (unaudited) - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 191,142,000 | $ 154,247,000 |
| Short-term investments | 0 | 24,605,000 |
| Accounts receivable | 42,365,000 | 44,021,000 |
| Supplies and inventory | 11,572,000 | 14,294,000 |
| Prepaid expenses and other current assets | 14,401,000 | 11,469,000 |
| Total current assets | 259,480,000 | 248,636,000 |
| Property, plant and equipment, net | 18,510,000 | 17,702,000 |
| Right-of-use assets, operating leases | 12,455,000 | 13,160,000 |
| Intangible assets, net | 164,744,000 | 174,866,000 |
| Goodwill | 698,920,000 | 695,891,000 |
| Restricted cash | 889,000 | 749,000 |
| Other assets | 6,116,000 | 5,418,000 |
| Total assets | 1,161,114,000 | 1,156,422,000 |
| Current liabilities: | ||
| Accounts payable | 12,895,000 | 11,911,000 |
| Accrued liabilities | 34,427,000 | 37,774,000 |
| Current portion of deferred revenue | 2,378,000 | 2,613,000 |
| Current portion of acquisition-related contingent consideration | 3,359,000 | 6,060,000 |
| Current portion of operating lease liabilities | 4,973,000 | 4,070,000 |
| Current portion of other liabilities | 119,000 | 186,000 |
| Total current liabilities | 58,151,000 | 62,614,000 |
| Deferred tax liabilities | 4,707,000 | 4,531,000 |
| Acquisition-related contingent consideration, net of current portion | 4,855,000 | 2,498,000 |
| Operating lease liabilities, net of current portion | 9,891,000 | 10,648,000 |
| Other liabilities | 792,000 | 931,000 |
| Total liabilities | 78,396,000 | 81,222,000 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.001 par value; 125,000,000 shares authorized, 72,643,156 and 71,959,454 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 73,000 | 72,000 |
| Additional paid-in capital | 1,520,638,000 | 1,500,191,000 |
| Accumulated deficit | (410,210,000) | (393,717,000) |
| Accumulated other comprehensive loss | (27,783,000) | (31,346,000) |
| Total stockholders’ equity | 1,082,718,000 | 1,075,200,000 |
| Total liabilities and stockholders’ equity | $ 1,161,114,000 | $ 1,156,422,000 |